Insmed (INSM) PT Raised to $55 at Stifel, Following Phase 2 WILLOW Study of INS1007 Results
Tweet Send to a Friend
Stifel analyst Adam Walsh raised ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
